Element of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of sliderElement of slider

2cSysBioMed at a glance

What we do and why?

At 2cSysBioMed we enable data-driven decision-making to gain tangible insight from high-dimensional biomedical data. Realizing precision medicine on this premise adds years to life and life to years.

What is our strategy?

The computer is incredibly fast, accurate, and stupid. Man is incredibly slow, inaccurate, and brilliant. The marriage of the two is a force beyond calculation. – Leo M. Cherne (1912–1999) 

Who are our clients?

Stakeholders in academia and industry who need consulting, analytics and data visualization services to effectively increase the value of their R&D by understanding complex biomedical data.

Why clients choose us?

Our proven capacity to distil the hypothetical “all one could do” to a pragmatic “what we should do” and transform data into actionable and impactful insight that advance their R&D.

Portfolio: Systems biomedicine, genomics and proteomics

Substituting invasive biopsy-based procedures for Sjögren’s syndrome-patient diagnosis and stratification for cancer-risk with proteomics-biomarker signatures obtained from saliva.
Mapping of transcriptional landscapes of emerging autoimmunity and inferring their dependence on disease-causing genomic regions using 2cSysBioMed’s proprietary network-based bioinformatics methodology.
RNA-sequencing of patients’ kidney biopsies reveals aspects of fibrosis and epithelial-mesenchymal transition paired with immune cell chemotaxis. Confirmed via expression deconvolution for virtual cell enumeration, chemokine::chemokine receptor mapping identifies molecular candidates suitable for drug repurposing initiatives.
Schematic of our systems-based translational medicine initiative for characterizing and modulating bacterial enzymes controlling severity and outcome of chronic inflammation in periodontitis.
Identification of non-classical modulators of tumor-associated macrophage differentiation form tumor secretomes. Integrated systems analyses of molecular landscapes underlying therapeutic effects in vitro and in vivo represent early drugs development milestones completed for prostate cancer immunotherapy.
Identification of a clinically applicable biomarker signature via translational molecular medicine that allows predicting prostate cancer recurrence. Such signatures enable precision medicine-based intervention defined on the basis of immune-cell subsets governing patients’ treatment outcomes.

Unlock your data

Services

At 2cSysBioMed we develop and provide customised systems-focused bioinformatics, advanced data visualization solutions and science communication materials as well as strategic consulting services.

We are thus well positioned to provide research groups, academia-industry partnerships and primary research firms with data-driven insights that inform pragmatic decisions and smart actions.

Advancing R&D in such fashion has since led to numerous peer review articles, published in  Nature Immunology, Nature Genetics, A&R, Rheumatology and AR&T among others, as well as other materials key for acquiring substantial new funding.

Blueprints

2cSysBioMed can rely on blueprints applied and validated in our peer-reviewed studies addressing:

Therapeutic areas

We bring significant domain knowledge with molecular medicine and immune-modulation as key therapeutic strategies to:

  • Autoimmunity (Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis, diabetes & Addison’s disease)

  • Oncology (cancer immunotherapy, metabolism & senescence)

  • Inflammation (periodontitis)

  • Nephrology (Fabry’s disease & CKD)

  • Infectious diseases (influenza, MMR, poliomyelitis, hepatitis A & B, rabies, EHEC, typhoid, cholera & P. aeruginosa)

Experimental science

By reason of education and appointments in bioengineering and experimental medicine we understand first hand strengths and limitations of:

  • DNA & RNAseq, RT-PCR, genetic engineering, gene regulation & translation

  • Antibody and MS-based proteomics, western blot, hybridoma technology, FACS & ELISA

  • Pathology, morphometry, IHC, confocal 3D & 4D microscopy

  • Biomarker-based diagnostic testing in biofluids

  • In vitro & in vivo models of vaccinology, autoimmunity & cancer

Deliverables

Deliverables may include strategic consulting sessions, data analyses reports as well as completing entire work packages and media for internal use, dissemination and peer-review.

Inquiry

Do you wish to informally discuss how our services may supplement your existing and future projects? We deliver services according to specifications accounted for per service or on an hourly basis.

Contact us!

About us

Profile

2cSysBioMed is founded on the basis of 20+ years of experience accumulated by its founder Nicolas Delaleu, PhD. His expertise derives from conducting translational research, designing and delivering bioinformatics tools and developing organisations that allow harnessing the power of the data revolution in medicine.

Our profile is also distinctively shaped by collaborations, appointments and research stays involving fields such as: medicine, molecular biology, biotechnology, statistics, computer science, software development, graphic design, technology transfer and project management.

We are located in Ticino in the southern part of Switzerland and in proximity to hubs such as Zürich, Basel and Milano.

Nicolas Delaleu, PhD

Portrait of Nicolas Delaleu, PhD: Founder of 2cSysBioMed with illustrations exemplifying applied network biology

Founder of 2cSysBioMed & Fmr. Group Leader R&D | Head Data Scientist & Translational Medicine Expert | Immunologist & Bioinformatician

Testimonials

Andrea Alimonti, MD, PhD

Director and PI Molecular Oncology, IOR, Switzerland & Professor of Experimental Oncology, ETH Zürich

Success of translational research increasingly hinges on understanding our “omics” datasets on the fly and their integration with novel concepts and existing data. Collaborating with Nicolas enabled us to do so for projects pertaining to cancer immunology, metabolism and senescence.

Roland Jonsson, DMD, PhD

Fmr. Broegelmann Chair of Immunology & Director, Bergen Research School in Inflammation, UiB, Norway

It’s inspiring how Nicolas’s capacity to think laterally paired with his pragmatic problem solving and positive can-do attitude enables harnessing the data revolution to advance medical research beyond what we thought possible when I first encouraged his independence as a scientist.

Hans-Peter Marti, Dr. med., Dr. h.c.

Professor of Nephrology, UiB, Norway

With 2cSysBioMed’s end-to-end consulting, analytics, visualization solutions and writing services, I know my “omics” data to be in good hands to maximize their academic impact, deliver on my contracts with industry and successfully compete for new funding.

Ivo Kwee, PhD

CTO and co-founder of BigOmics Analytics, Lugano, Switzerland

Bouncing ideas with Nicolas is always a thought-provoking and engaging experience; be it about how to best analyse, integrate and visualise “omics” data, how to improve bioinformatics services, or when discussing entrepreneurship.

Ammon B. Peck, PhD

Fmr. Professor & Assoc. Dean for Research and Graduate Studies, Vet. Med., UF, USA

Having collaborated with Nicolas for decades, I greatly respect his ability to deal with ideas, technologies and discoveries arising in fields other than the ones he knows. With enthusiasm and determination he is at ease applying this knowledge to advance medical research.

Piotr Mydel, MD, PhD

Professor of Medical Science, UJ, Poland & Professor of Immunology, UiB, Norway

To me, achieving seamless and tight integration of medical research with data science is key to advance discoveries towards sustainable technology transfer initiatives. In this process, the services of Nicolas and 2cSysBioMed were key to secure funding and publish research efficiently.

Alberto Toso, PhD

SVP and Head Oncology, Alentis Therapeutics, Basel, Switzerland

Advanced analytics paired with ingenious visualization methodologies as developed by Nicolas demonstrate how tangible insight can be unlocked form biomedical data. His firsthand experience of experimental research in autoimmunity and drug discovery are thereby invaluable.

Silvia Monticelli, PhD

PI Molecular Immunology, IRB, Switzerland

2cSysBioMed’s proprietary methodologies to map transcriptional landscapes and their analyses by Nicolas Delaleu efficiently guided our experimental approach to delineate a molecular network regulating the proinflammatory phenotype of T-cells in humans.

Diletta di Mitri, PhD

PI Tumor Microenvironment Unit, Humanitas Research Hospital, Italy

When studying reprogramming a tumor’s microenvironment as a novel therapeutic strategy, Nicolas’s work was crucial for candidate selection and delineating immunomodulators’ therapeutic properties based on transcriptomics and proteomics from in vitro and in vivo studies.

Kjell Petersen, PhD

PI Computational Biology Unit, UiB & ELIXIR, Norway

Nicolas Delaleu’s skill to drive software design and development for increasing R&D efficiency in molecular medicine and interact with people with very different backgrounds is critical to bring applied data science to biomedical research.

Contact us

    2cSysBioMed

    Via Contra 605
    6648 Minusio
    Switzerland

    E: info@2cSysBioMed.com
    W: www.2cSysBioMed.com